• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

FDA starts review of Argenx drug in rare disease CIDP

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 20, 2024 at 11:12: AM
via The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the company tries to turn around a run of bad news with the drug.

article source
 




Top Bottom
Back
Quote